Market Overview:
The global human fibrinogen market is expected to grow at a CAGR of 5.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing incidence of congenital fibrinogen deficiency and surgical procedures. Additionally, the growing demand for human fibrinogen concentrate from emerging markets is also contributing to the growth of this market. However, factors such as high cost and limited availability are restraining the growth of this market. On the basis of type, human fibrinogen concentrate held a major share in 2017 and is expected to continue its dominance during the forecast period. This can be attributed to its advantages over animal-based concentrates such as low risk of transmitting infections and better patient outcomes. On the basis of application, congenital fibrinogen deficiency held a major share in 2017 and is expected to continue its dominance duringthe forecast period owingtoits high prevalence across all regions studied herein.
Product Definition:
Human Fibrinogen is a glycoprotein in the blood that is converted to fibrin during clotting. It is important for blood clotting and wound healing.
Human Fibrinogen Concentrate:
Human fibrinogen is a protein that helps in the formation of blood clots. It is produced by both, males and females. However, women are more prone to deficiency as they tend to have less powerful immune systems. Deficiency of human fibrinogen may lead to life-threatening diseases such as bleeding disorder called thrombocytopenia and liver disease called porfimer sodium induced bleeding disorder (PSID).
Animal Fibrinogen Concentrate:
Animal fibrinogen is used as a raw material for the production of human fibrinogen. It is extracted from animal blood and its concentration varies with species. For instance, it is highest in humans compared to other animals followed by cattle and sheep. The extraction process of animal fibrinogen may cause an allergic reaction in some people which leads to swelling of the tongue, face, or other parts of the body; this is called anaphylaxis.
Application Insights:
The global human fibrinogen market is segmented on the basis of application into congenital fibrinogen deficiency, surgical procedures and others. The surgical procedures segment dominated the overall market in terms of revenue share in 2017. This can be attributed to factors such as increasing number of surgeries globally and technological advancements that have led to an increase in efficiency during surgeries. For instance, laparoscopic gallbladder surgery has gained widespread popularity due to its low risk and short recovery time as compared to conventional open surgery techniques.
Congenital fibrinogen deficiency was estimated to be one of the least lucrative applications for HFG across all regions with a share less than 1% in 2017 owing to lack of awareness about this product among patients suffering from this condition coupled with a paucity of available clinical data regarding its usage for treating congenital disorders associated with FVIII or FIX activity level below normal levels.
Regional Analysis:
In 2017, North America dominated the global market owing to the presence of well-established healthcare infrastructure and high awareness levels amongst patients. Moreover, increasing prevalence of thrombosis in this region is anticipated to fuel demand for human fibrinogen over the forecast period. For instance, according to a study published by National Center for Biotechnology Information (NCBI), in U.S., approximately 4 million people suffer from deep vein thrombosis (DVT) annually with an average age of 53 years and male predominance.
Asia Pacific is expected to witness lucrative growth over the forecast period due to rising disposable income coupled with improving healthcare facilities & infrastructure in emerging countries such as China & India. In addition, growing medical tourism industry will also boost product demand further driving regional market growth during the forecast period (2018 - 2030).
Growth Factors:
- Increasing demand for fibrinogen products for various medical applications such as surgery, wound healing, and blood clotting is expected to drive the growth of the human fibrinogen market over the forecast period.
- Rising prevalence of bleeding disorders and other diseases that require treatment with fibrinogen products is also anticipated to fuel market growth.
- Growing awareness about benefits of using fibrinogen products is projected to boost demand in the coming years.
- Technological advancements in manufacturing processes are likely to result in increased production of high-quality human fibrinogen products, thereby propelling market expansion over the forecast period.
Scope Of The Report
Report Attributes
Report Details
Report Title
Human Fibrinogen Market Research Report
By Type
Human Fibrinogen Concentrate, Animal Fibrinogen Concentrate
By Application
Congenital Fibrinogen Deficiency, Surgical Procedures
By Companies
CSL Behring, LFB Group, Shanghai RAAS Blood Products, Jiangxi Boya Bio-Pharmaceutical, Hualan Biological Engineering, Harbin Pacific Biopharmaceutical, GREEN CROSS, Shanghai XinXing Medical, Octapharma
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
247
Number of Tables & Figures
173
Customization Available
Yes, the report can be customized as per your need.
Global Human Fibrinogen Market Report Segments:
The global Human Fibrinogen market is segmented on the basis of:
Types
Human Fibrinogen Concentrate, Animal Fibrinogen Concentrate
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Congenital Fibrinogen Deficiency, Surgical Procedures
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- CSL Behring
- LFB Group
- Shanghai RAAS Blood Products
- Jiangxi Boya Bio-Pharmaceutical
- Hualan Biological Engineering
- Harbin Pacific Biopharmaceutical
- GREEN CROSS
- Shanghai XinXing Medical
- Octapharma
Highlights of The Human Fibrinogen Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Human Fibrinogen Concentrate
- Animal Fibrinogen Concentrate
- By Application:
- Congenital Fibrinogen Deficiency
- Surgical Procedures
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Human Fibrinogen Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Human fibrinogen is a protein that helps to form blood clots.
Some of the key players operating in the human fibrinogen market are CSL Behring, LFB Group, Shanghai RAAS Blood Products, Jiangxi Boya Bio-Pharmaceutical, Hualan Biological Engineering, Harbin Pacific Biopharmaceutical, GREEN CROSS, Shanghai XinXing Medical, Octapharma.
The human fibrinogen market is expected to register a CAGR of 5.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Human Fibrinogen Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Human Fibrinogen Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Human Fibrinogen Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Human Fibrinogen Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Human Fibrinogen Market Size & Forecast, 2020-2028
4.5.1 Human Fibrinogen Market Size and Y-o-Y Growth
4.5.2 Human Fibrinogen Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Human Fibrinogen Concentrate
5.2.2 Animal Fibrinogen Concentrate
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Congenital Fibrinogen Deficiency
6.2.2 Surgical Procedures
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Human Fibrinogen Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Human Fibrinogen Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Human Fibrinogen Concentrate
9.6.2 Animal Fibrinogen Concentrate
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Congenital Fibrinogen Deficiency
9.10.2 Surgical Procedures
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Human Fibrinogen Concentrate
10.6.2 Animal Fibrinogen Concentrate
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Congenital Fibrinogen Deficiency
10.10.2 Surgical Procedures
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Human Fibrinogen Concentrate
11.6.2 Animal Fibrinogen Concentrate
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Congenital Fibrinogen Deficiency
11.10.2 Surgical Procedures
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Human Fibrinogen Concentrate
12.6.2 Animal Fibrinogen Concentrate
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Congenital Fibrinogen Deficiency
12.10.2 Surgical Procedures
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Human Fibrinogen Concentrate
13.6.2 Animal Fibrinogen Concentrate
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Congenital Fibrinogen Deficiency
13.10.2 Surgical Procedures
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Human Fibrinogen Market: Competitive Dashboard
14.2 Global Human Fibrinogen Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 CSL Behring
14.3.2 LFB Group
14.3.3 Shanghai RAAS Blood Products
14.3.4 Jiangxi Boya Bio-Pharmaceutical
14.3.5 Hualan Biological Engineering
14.3.6 Harbin Pacific Biopharmaceutical
14.3.7 GREEN CROSS
14.3.8 Shanghai XinXing Medical
14.3.9 Octapharma
